OSE Immunotherapeutics and ARCAGY – GINECO Announce Initiation of a Randomized Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Pembrolizumab in Ovarian Cancer
This clinical trial will be sponsored and conducted by the French oncology cooperative group ARCAGY-GINECO and supported by Merck Sharp... View Article
New member | Orthopus
ORTHOPUS designs open-source technical aids for physical disabilities at fair prices. Based in Nantes, this company develops two ranges of... View Article
Valneva and Pfizer announce initiation of phase 2 study for Lyme disease vaccine candidate
The Phase 2 study will include both adult and pediatric subjects with an aim to support acceleration of the vaccine... View Article
The European Patent Office has granted McSAF a patent for DAR 4 antibody-drug conjugates technology
The European Patent Office (EPO) has granted the patent number EP3521314 on the McSAF Inside® technology to access DAR 4... View Article
Valneva initiates phase 3 clinical lot consistency study for its single-shot chikungunya vaccine candidate
Valneva SE, a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need, today announced that... View Article
New member | Parean Biotechnologies
Parean Biotechnologies is an European expert of deep immune phenotyping, and multi-omics data analysis. With co-founders know-how, built in academic... View Article
Pherecydes Pharma is adding to its patent portfolio with two new patents granted in the United States
Pherecydes Pharma, a biotechnology company specialized in precision phagotherapy designed to fight resistant and/or complex bacterial infections, recently announced the... View Article
Thermo Fisher Scientific acquires viral vector manufacturing business from Novasep
Thermo Fisher Scientific Inc., the world leader in serving science, and Groupe Novasep SAS (Novasep), a leading supplier of services... View Article
The latest edition of the Panorama France HealthTech produced by France Biotech
Faced with a health crisis of historic proportions and the related unprecedented challenges, the healthcare sector is once again demonstrating... View Article
OSE Immunotherapeutics enters a loan agreement of up to €25 Million with the European Investment Bank
This loan will further support the progress and expansion of OSE Immunotherapeutics’ lead clinical development programs in diseases with high... View Article